caratherapeutics.com (TVRD) - Cash per Share

The development of drugs for renal pruritus is independent of macroeconomics and seasonality, demonstrating high resilience. The estimated cash per share clearly illustrates the current situation, where the 1.68 mark characterizes this parameter. Cara Therapeutics Inc (TVRD) focuses on therapy for dialysis patients, however, management is currently urgently reducing headcount following failed trials in an attempt to restore investor confidence.
Comprehensive metric breakdowns and analytics for Cara Corp (TVRD)

By outsourcing production and clinical trials, Cara Therapeutics Inc (TVRD) minimizes capital expenditures while maintaining high operational flexibility. The trend in cash per share reflects the actual liquidity reserve, allowing investors to distinguish fundamental value from illusory cheapness and timely identify systemic business degradation by analyzing abnormal liquidity spikes on this chart.